ZLAB Zai Lab Ltd

ZLAB financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1704292 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Aug 6, 2026 Data checked: Oct 21, 2026
Showing 3 of 11 annual and 0 of 26 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Large accelerated filer
Entity Type
Operating
Public Float
$3.80B (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
E9
Fiscal Year End
December (1231)
Phone
862161632588
EIN
000000000
Headquarters
SHANGHAI
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Zai Lab Ltd (2017–2026)

▼ Key Metrics (TTM)

As of Jun 30, 2026
Financials
Revenue
$449.61M
Net Income
$-188.21M
Total Assets
$1.07B
Total Equity
$607.04M
Total Debt
-
Free Cash Flow
$-139.57M
Ratios
Gross Margin
56.5%
Operating Margin
-58.7%
Net Margin
-41.9%
Return on Equity
-31%
Return on Assets
-17.5%
Current Ratio
2.13x
FCF / Assets
-13%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Zai Lab Ltd generated $460.16M of revenue in fiscal 2025, with net loss of $175.54M and an operating cash outflow of $150.79M. At $460.16M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. Revenue was 15.3% above fiscal 2024 revenue of $398.99M, marking a year-over-year increase. Diluted earnings per share were -$0.16, translating the period’s attributable earnings into the amount reported for each diluted share. The diluted weighted-average share count was 1.10B, linking total earnings with the per-share result received by shareholders. Total assets stood at $1.17B, showing the scale of resources supporting revenue, earnings, liquidity, and financing. The revenue-to-assets relationship was 0.39x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $269.64M, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. The gross-profit relationship equaled 58.6% of revenue, quantifying the portion retained before operating expenses were recognized. Operations produced a $229.43M operating loss before non-operating and tax effects. Relative to revenue, the operating deficit measured 49.9%, showing the shortfall after operating costs. The company ended the period with a net loss of $175.54M, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 38.1% after all recognized items. Negative EBITDA totaled $214.42M, confirming that the earnings deficit remained before depreciation and amortization. The pretax result was a loss of $178.46M, establishing the deficit before tax effects. Measured against revenue, the pretax deficit represented 38.8%. An income-tax benefit of $2.93M improved the final result relative to pretax income or loss. The loss-to-equity relationship was 24.5%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 15.0%. Compared with a $257.10M net loss in fiscal 2024, the current loss improved to $175.54M.

Liquidity and Capital Structure

The company held $1.17B of assets against $456.88M of liabilities and $715.50M of equity, revealing how the asset base was financed. At period end, current assets of $1.02B compared with current liabilities of $416.17M, defining the company’s short-term resource position. Current assets covered current liabilities by 2.45x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $679.57M, separating immediately recognizable cash resources from the rest of the current-asset base. Cash and equivalents represented 163.3% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. Equity equaled 61.0% of assets, showing the shareholder-capital layer within the company’s balance sheet. Liabilities represented 39.0% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 58.0% of total assets, showing the liquid cash component within the company’s broader resource base. Total assets were 1.1% lower than fiscal 2024 assets of $1.19B, measuring the company’s own balance-sheet change. Against $840.90M of equity in fiscal 2024, the current book-equity balance moved 14.9% and ended lower. Cash and equivalents were 51.1% higher than fiscal 2024 cash of $449.67M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Operating activities used $150.79M of cash, resulting in an operating cash outflow for the year. Capital spending of $8.10M added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $158.89M, leaving a cash deficit after capital spending and reducing financial flexibility. Free-cash-flow margin was -34.5%, reflecting a cash deficit equal to 34.5% of revenue after capital spending. The free-cash-flow deficit equaled 13.6% of total assets, placing the cash shortfall against the company’s resource base.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Zai Lab Ltd
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $460.16M $398.99M $266.72M
Cost of Revenue $190.52M $147.12M $95.82M
Gross Profit $269.64M $251.87M $170.90M
OPERATING EXPENSES
R&D Expense $220.90M $234.50M $265.87M
SG&A Expense $277.61M $298.74M $281.61M
Other Operating Expenses (derived) $561.00K $742.00K $-10.00M
Operating Income $-229.43M $-282.12M $-366.57M
NON-OPERATING INCOME / EXPENSE
Interest Expense - $2.25M $0
Interest Income $33.05M $37.11M $39.80M
Other Income/Expense $3.54M $5.30M $7.01M
Pretax Income $-178.46M $-257.10M $-334.62M
Income Tax $-2.93M $0 $0
Net Income $-175.54M $-257.10M $-334.62M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.16 $-0.26 $-0.35
Diluted Shares 1.10B 989.48M 966.39M
EBITDA $-214.42M $-270.26M $-357.54M
Depreciation & Amortization $15.01M $11.86M $9.03M
Balance Sheet
ASSETS
Cash & Equivalents $679.57M $449.67M $790.15M
Short-term Investments $10.00M $330.00M $16.30M
Accounts Receivable $106.12M $85.18M $59.20M
Inventory $74.75M $39.88M $44.83M
Other Current Assets $36.68M $41.53M $23.00M
Current Assets $1.02B $1.05B $939.61M
PP&E (Net) $47.39M $47.96M $53.73M
Intangible Assets $76.14M $56.03M $13.39M
Other Noncurrent Assets $3.05M $5.77M -
Noncurrent Assets $153.10M $135.27M $96.69M
Total Assets $1.17B $1.19B $1.04B
LIABILITIES
Accounts Payable $141.61M $100.91M $112.99M
Short-term Debt $204.53M $131.71M $0
Other Current Liabilities $63.68M $58.72M $82.97M
Current Liabilities $416.17M $299.39M $203.07M
Other Noncurrent Liabilities $0 $325.00K $325.00K
Noncurrent Liabilities $40.72M $45.47M $37.11M
Total Liabilities $456.88M $344.86M $240.18M
EQUITY
Common Stock $7.00K $7.00K $6.00K
Additional Paid-in Capital $3.34B $3.26B $2.98B
Retained Earnings $-2.63B $-2.45B $-2.20B
Accumulated OCI $29.70M $50.52M $37.63M
Total Equity $715.50M $840.90M $796.12M
Total Liabilities & Equity $1.17B $1.19B $1.04B
SUPPLEMENTAL
Shares Outstanding 1.11B 1.08B 972.24M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-150.79M $-214.87M $-198.18M
Capital Expenditures $8.10M $5.66M $7.21M
Cash from Investing $307.87M $-375.19M $-10.78M
Cash from Financing $72.35M $349.89M $-6.43M
Free Cash Flow $-158.89M $-220.53M $-205.39M
Beginning Cash (CFS) $550.78M $791.26M $1.01B
Net Change in Cash $229.43M $-240.17M $-215.39M
Effect of FX on Cash $478.00K $-310.00K $-2.62M
Calculated Ending Cash $780.69M $550.78M $791.26M
Cash per BS $679.57M $449.67M $790.15M
Cash scope difference (CFS − BS) $101.12M $101.11M $1.11M
Cash per CFS $780.69M $550.78M $791.26M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Zai Lab Ltd's annual revenue?

Zai Lab Ltd reported $449.61M in revenue for trailing twelve months (ending June 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Zai Lab Ltd profitable?

No. Zai Lab Ltd reported $-188.21M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does Zai Lab Ltd generate free cash flow?

No. Free cash flow was $-139.57M for trailing twelve months. Operating cash flow was $-133.38M.